Vaccine Receives FDA Breakthrough Designation for Recurrent Respiratory Papillomatosis Treatment скачать в хорошем качестве

Vaccine Receives FDA Breakthrough Designation for Recurrent Respiratory Papillomatosis Treatment

Clinical trial results suggest potential treatment for recurrent respiratory papillomatosis Therapy could be the first non-surgical option available for debilitating disease Patients suffering from the debilitating disease recurrent respiratory papillomatosis (RRP) may soon have hope thanks to the positive results from a clinical trial administered across eight sites including UC Davis Health. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to INOVIO Pharmaceuticals for their experimental vaccine INO-3107 as a potential treatment for patients with recurrent respiratory papillomatosis based on data from Phase 1 and 2 of the clinical trial. If approved, INO-3107 could be the first non-surgical treatment available for recurrent respiratory papillomatosis, which is caused by infection with two types of human papillomavirus (HPV). The FDA's Breakthrough Therapy designation is a process designed to expedite the development and review of promising drugs that would treat a serious condition.